Could a parasite drug boost cancer immunotherapy? new trial investigates
NCT ID NCT05318469
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding ivermectin (a drug used for parasitic infections) to standard immunotherapy drugs (balstilimab or pembrolizumab) can shrink tumors in people with metastatic triple-negative breast cancer. The trial has two phases: first, finding the safest dose of ivermectin, and second, checking how well the combination works. About 34 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivermectin combined with balstilimab or pembrolizumab
What this could lead to
If it works, this could offer a new treatment option for people with metastatic triple-negative breast cancer, potentially shrinking tumors and extending life.
What could go wrong
This is an early-phase trial with only 34 participants, so results are uncertain. Ivermectin is not a standard cancer drug, and combining it with immunotherapy may cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact